Skip to main content

R

  • Chapter
  • 193 Accesses

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Drugs Fut (1994) 19(1):70-71

    Google Scholar 

  2. Drugs Fut (1991) 16(1):19-22

    Google Scholar 

  3. Morii M, Takata H, Fujisaki H, Takeguchi N (1990) Biochem Pharmacol 39:661–667

    Article  PubMed  CAS  Google Scholar 

  4. Morii M, Hamatani K, Takeguchi N (1995) Biochem Pharmacol 49:1729–1734

    Article  PubMed  CAS  Google Scholar 

  5. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E (1995) Aliment Pharmacol Ther 9:363–378

    Article  PubMed  CAS  Google Scholar 

  6. Tomiyama Y, Morii M, Takeguchi N (1994) Biochem Pharmacol 48:2049–2055

    Article  PubMed  CAS  Google Scholar 

  7. Fujisaki H, Shibata H, Oketani K, Murakami M, Fujimoto M, Wakabayashi T, Yamatsu I, Yamaguchi M, Sakai H, Takeguchi N (1991) Biochem Pharmacol 42:321–328

    Article  PubMed  CAS  Google Scholar 

  8. Hirai M, Azuma T, Ito S, Kato T, Kohli Y (1995) J Gastroenterol 30:461–464

    Article  PubMed  CAS  Google Scholar 

  9. Clarke ECG (1969) Isolation and Identification of Drugs, The Pharmaceutical Press, London, S. 534

    Google Scholar 

  10. Schnider O, Grüssner AA (1949) Helv Chim Acta 32:821–829

    Article  PubMed  CAS  Google Scholar 

  11. Moffat AC (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, The Pharmaceutical Press, London, S. 956

    Google Scholar 

  12. Steal AH, Gill R, Wright T, Gibbs JP et al. (1982) Analyst 107:1106–1168

    Article  Google Scholar 

  13. Braga PC, Fossati A, Vemercati MG, Caputo R, et al. (1994) Dextrorphan and dextromethorphan: comparative antitussive effects on guinea pigs. Drugs Exp Clin Res 20:199–203

    PubMed  CAS  Google Scholar 

  14. Drugs Fut (1986) 11:387-388

    Google Scholar 

  15. Carrupt PA, Tsai RS, El Tayar N, De Paulis T, Hoegberg T (1991) Helv Chim Acta 74(5):956–968

    Article  CAS  Google Scholar 

  16. Nilsson LB (1990) J Chromatogr 506:253–264

    Article  CAS  Google Scholar 

  17. Adam MJ, Grierson JR, Jivan S (1989) Appl Radiat Isot 40:91–92

    Article  CAS  Google Scholar 

  18. Pike VW, Kensett MJ, Turton DR, Waters S, Silvester DJ (1990) Appl Radiat Isot 41:483–492

    Article  CAS  Google Scholar 

  19. Brithish Isles Raclopride study group (1992) A double-blind comparison of raclopride and haloperidol in the acute phase of schizophenia. Acta Psychiat Scand 86:391–398

    Article  Google Scholar 

  20. Patoia L, Berchicci P (1990) Drug Fut 15:689–694

    Google Scholar 

  21. Cavalleri B, Pagani H, Volpe F, Selva E, Parenti F (1984) J Antibiot 37:309–317

    Article  PubMed  CAS  Google Scholar 

  22. Kurz M, Guba W (1996) Biochem 35:12570–12575

    Article  CAS  Google Scholar 

  23. Sommer EA, Reynolds PE (1990) Antimicrob Agents Chem 34:413–419

    Article  Google Scholar 

  24. Somner EA, Reynolds PE (1990) Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob Agents Chemother 34:413–419

    Article  PubMed  CAS  Google Scholar 

  25. O’Hare MD, Ghosh G, Felmingham D, Grüneberg RN (1990) In vitro studies with ramoplanin (MDL 62,198): a novel lipoglycopeptide antimicrobial. J Antimicrob Agents Chemother 25:217–220

    Article  Google Scholar 

  26. Biavasco F, Manso E, Varaldo PE (1991) In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimicrob Ag Chemother 35:195–197

    Article  CAS  Google Scholar 

  27. Johnson CC, Taylor S, Pitsakis P, May P, Levison ME (1992) Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Antimicrob Agents Chemother 36:2342–2345

    Article  PubMed  CAS  Google Scholar 

  28. Collins LA, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC (1993) In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother 37:1364–1366

    Article  PubMed  CAS  Google Scholar 

  29. Mar 31, S. 267

    Google Scholar 

  30. Drug Fut (1995) 20:480-482

    Google Scholar 

  31. Pipkin GA, Wood JR (1997) Drug Today 33:431–451

    CAS  Google Scholar 

  32. Sadler PJ, Sun H (1995) J Chem Soc, Dalton Trans:1395-1401

    Google Scholar 

  33. Lacey LF, Frazer NM, Keene ON et al. (1994) Eur J Clin Pharmacol 47:177–180

    Article  PubMed  CAS  Google Scholar 

  34. Tillman LA, Drake FM, Dixon JS et al. (1996) Aliment Pharmacol Ther 10:459–467

    Article  PubMed  CAS  Google Scholar 

  35. Syntex, zit. nach CA 102:166777 (U.S.A.), EP 126449 Al 28.11.1984

    Google Scholar 

  36. Richter, zit. nach CA 117:48614, Gedeon EP 483932 Al 06.05.1992

    Google Scholar 

  37. Lodge JPA, Lam FT, Perry SL, Giles GR (1990) Transplantation 50(5):755–759

    Article  PubMed  CAS  Google Scholar 

  38. Delee E (1987) Chromatographia 24:357–359

    Article  CAS  Google Scholar 

  39. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD (1996) Ranolazine stimulates glucose oxidation in normioxic, ischemic, and reperfused ischemic rat hearts. Circulation 93:135–142

    Article  PubMed  CAS  Google Scholar 

  40. Gralinski MR, Black SC, Kilgore KS, Chou AY, et al. (1994) Cardioprotetive effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res 28:1231–1237

    Article  PubMed  CAS  Google Scholar 

  41. Allen TJ, Chapman RA (1996) Effects of ranolazine on L-type clacium channel currents in guinea-pig single ventricular myocytes. Br J Pharmacol 118:249–254

    Article  PubMed  CAS  Google Scholar 

  42. Wyatt KM, Skene C, Veitch K, Hue L, et al. (1995) The antianginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondria. Biochem Pharmacol 50:1599–1606

    Article  PubMed  CAS  Google Scholar 

  43. Jain D, Dasgupta P, Hughes LO, Lahiri A, et al. (1990) Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium. Eur J Clin Pharmacol 38:11–114

    Article  Google Scholar 

  44. Cocco G, Rousseau MF, Bouvy T, Cheron P, et al. (1992) Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol 20:131–138

    PubMed  CAS  Google Scholar 

  45. Thadani U, Ezekowitz M, Fenney L, Chiang YK (1994) Double-blind efficacy and safety study of a novel antiischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group. Circulation 90:726–734

    Article  PubMed  CAS  Google Scholar 

  46. Uchida M, Tabusa F, Komatsu M, Kanbe T, Nakagawa K (1985) Chem Pharm Bull 33:3775–3786

    Article  PubMed  CAS  Google Scholar 

  47. Otsubo K, Morita S, Uchida M, Yamasaki K, Kanbe T, Shimizu T (1991) Chem Pharm Bull 39:2906–2909

    Article  PubMed  CAS  Google Scholar 

  48. Monographie (1988) Drugs Fut 13:959–961

    Google Scholar 

  49. Shioya Y, Shimizu T (1988) J Chromatogr 434:283–287

    Article  PubMed  CAS  Google Scholar 

  50. Yamasaki K, Ishiyama H, Imaizumi T, Kanabe T, Yabuuchi Y (1989) Japan J Pharmacol 49:441–448

    Article  CAS  Google Scholar 

  51. Kleine A, Kluge S, Peskar BM (1993) Dig Dis Sci 38:1441–1449

    Article  PubMed  CAS  Google Scholar 

  52. Ishihara K, Komuro Y, Nishiyama N, Yamasaki K, Hotta K (1992) Arzneim-Forsch/Drug Res 42:1462–1466

    CAS  Google Scholar 

  53. Ogino K, Hobara T, Ishiyama H, Yamasaki K, Kobayashi H, Izumi Y, Oka S (1992) Eur J Pharmacol 212:9–13

    Article  PubMed  CAS  Google Scholar 

  54. Drugs Fut (1994) 19(12):1088-1092

    Google Scholar 

  55. Feldman PL, James MK, Brackeen MF, Johnson MR, Leighton HJ (Glaxo Inc.) n-Phenyl-N-(4-piperidinyl)amides useful as analgetics, EP 383579, JP 90300167, US 5019583

    Google Scholar 

  56. Feldman PL, James MK, Brackeen MF, Bilotta JM, Schuster SV, Lahey AP, Lutz MW, Johnson MR, Leighton HJ; Design, synthesis ans pharmacological evaluation of ultra-short-to long-acting opoid analgetics. (1991) J Med Chem 348(7):2202–2208

    Article  Google Scholar 

  57. Glass PS, Hardman D, Kamiyama Y, Quill TJ, Marton G, Donn KH, Grosse CM, Herrmann D (1993) Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). Anesth Analg 77:1031–1040

    Article  PubMed  CAS  Google Scholar 

  58. Egan TD, Minto CF, Hermann DJ, Barr J, Muir KT, Shafer SL (1996) Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Anesthesiology 84:821–833

    Article  PubMed  CAS  Google Scholar 

  59. Lemmens HJ (1995) Pharmacokinetic-pharmacodynamic relationships for opioids in balanced anaesthesia. Clin Pharmacokinet 29:231–242

    Article  PubMed  CAS  Google Scholar 

  60. Westmoreland CL, Hoke JF, Sebel PS, Hug CC JR, Muir KT (1993) Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology 79:893–903

    Article  PubMed  CAS  Google Scholar 

  61. Egan TD, Lemmens HJ, Fiset P, Hermann DJ, Muir KT, Stanski DR, Shafer SL (1993) The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology 79:881–892

    Article  PubMed  CAS  Google Scholar 

  62. Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, Camporesi EM (1995) Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil. J Pharmacol Exp Ther 274:34–39

    PubMed  CAS  Google Scholar 

  63. Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw LL, Peng AW, Jamerson Bd (1995) Initial clinical experience with remifentanil, a new opioid metabolized by esterases. Anesth Analg 81:619–623

    PubMed  CAS  Google Scholar 

  64. Schraag S, Georgieff M (1995) Intravenous anesthesia-current aspects. Anaesthesiol Intensivmed Notfallmed Schmerzther 30:469–478

    Article  CAS  Google Scholar 

  65. Lang E, Kapila A, Shlugman D, Hoke JF, Sebel PS, Glass PS (1996) Reduction of isoflurane minimal alveolar concentration by remifentanil. Anesthesiology 85:721–728

    Article  PubMed  CAS  Google Scholar 

  66. Hogue CW, Bowdle TA, O’Leary C, Duncalf D, Miguel R, Pitts M, Streisand J, Kirvassilis G, Jamerson B, McNeal S, Battenhorst R (1996) A multicenter evaluation of total intraveous anesthesia with remifentanil and propofol for elective inpatient surgery. Anesth Analg 83:279–285

    PubMed  CAS  Google Scholar 

  67. Fragen RJ (1995) Implications of the use of remifentanil on patient outcomes. Eur J Aneaesthesiol suppl 10:75–76

    CAS  Google Scholar 

  68. Sebel PS, Hoke JF, Westmoreland C, Hug CCJ, Muir KT, Sziam F (1995) Histamine concentrations and hemodynamic responses after remifentanil. Anesth Analg 80:990–993

    PubMed  CAS  Google Scholar 

  69. Himmelmann A, Bergbrant A, Svensson A, Hansson L, Aurell M (1996) Remikiren (Ro 42-5892) — an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the reinin-angiotensin-system. Am J Hypertension:517-522

    Google Scholar 

  70. Johnston CI (1990) Biochemistry and pharmacology of the renin-angiotensin system. Drugs 39:21–31

    Article  PubMed  CAS  Google Scholar 

  71. Van den Meiracker AH, Admiraal PJJ, Derkx FHM, Kleinbloesem C, Manin’t Veld AJ (1990) Comparison of Blood pressure and angiotensin responses to the renin inhibitor RO 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension. J Hypertension 11:831–838

    Article  Google Scholar 

  72. Camenzind E, Nussberger J, Juillerat L, Munafo A, Fischli W (1991) Effect of the renin response during renin inhibition: oral Ro 42-5892 in normal humans. J Cardiovasc Pharmacol 18:299–307

    Article  PubMed  CAS  Google Scholar 

  73. Weber C, Birnböck H, Leube J, Kobrin I, Kleinbloesem CH (1993) Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients. Br J Clin Pharmacol 36:547–554

    Article  PubMed  CAS  Google Scholar 

  74. Viskoper RJ, Charlon V, Laszt A, Yosefi C, Bock J (1994) Time dependency of the antihypertensive efficacy of the new renin inhibitor RO 42-5892. J Human Hypertension 8:133–136

    CAS  Google Scholar 

  75. Van Paassen P, de Zeeuw D, de Jong PE. Renal and systemic effects of the renin inhibitor remikiren in patients with essential hypertension. J Cardiovasc Pharmacol 26:39-45

    Google Scholar 

  76. Kobrin I, Viskoper RJ, Laszt A, Bock J, Weber C (1993) Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension. Am J Hypertension 6:349–356

    CAS  Google Scholar 

  77. Kleinbloesem CH, Weber C, Fahrner E, Dellenbach M, Welker H (1993) Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. Clin Phamacol Ther 53:585–592

    Article  CAS  Google Scholar 

  78. Widman M, Nilsson LB, Bryske B, Lundström J (1993) Arzneim Forsch 43:287–297

    CAS  Google Scholar 

  79. Nilsson LB (1990) J Chromatogr 526:139–150

    Article  PubMed  CAS  Google Scholar 

  80. Florvall GL, Oegren SO (1979) CA 1109484 A2, zit. nach CA (1982) 96:68629

    Google Scholar 

  81. Pettersson C, Gioeli C (1993) Chirality 5:241–245, zit. nach CA (1994) 120:207658

    Article  CAS  Google Scholar 

  82. Haupt D, Pettersson C, Westerlund D (1993) Chirality 5:224–228, zit. nach CA (1994) 120:207657

    Article  CAS  Google Scholar 

  83. Kerwin R, Taylor D (1996) New antipsychotics. A review of their current status and clinical potential. CNS Drugs 6:71–82

    Article  CAS  Google Scholar 

  84. Owens DGC (1996) Adverse effects of antipsychotic agents. Drugs 51:896–930

    Google Scholar 

  85. King FD, Hadley MS, Joiner KT, Martin RT, Sanger GJ, Smith DM, Smith GE, Smith P, Turner DH, Watts EA (1993) J Med Chem 36:683–689

    Article  PubMed  CAS  Google Scholar 

  86. Collin S, Moureau F, Quintero MG, Vercauteren DP, Evrard G, Durant F (1995) J Chem Soc Perkin Trans II:77–84

    Google Scholar 

  87. Robertson CS, Evans DFR, Hicks F, Atkinson M (1988) Aliment Pharmacol Ther 2:501–506

    Article  PubMed  CAS  Google Scholar 

  88. Staniforth DH, Pennick M (1990) Eur J Clin Pharmacol 38:161–164

    Article  PubMed  CAS  Google Scholar 

  89. Craig DA, Clarke DE (1991) Br J Pharmacol 102:563–564

    Article  PubMed  CAS  Google Scholar 

  90. Sanger GJ (1987) Br J Pharmacol 91:77–87

    Article  PubMed  CAS  Google Scholar 

  91. Cooper SM, McClelland CM, McRitchie B, Turner DH (1986) Br J Pharmacol 88:383P

    Google Scholar 

  92. Mackie AD, Ferrington C, Cowan S, Merrick MV, Baird JD, Palmer KR (1991) Aliment Pharmacol Ther 5:135–142

    Article  PubMed  CAS  Google Scholar 

  93. Knoll & Co. (1899) DRP 103.857

    Google Scholar 

  94. Clarke EGC (1986) Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London, S. 959

    Google Scholar 

  95. Beilstein E4 VI, S. 5.672

    Google Scholar 

  96. Hoshi A, Castañer J (1994) Drugs Fut 19:122–124

    Google Scholar 

  97. Dormoy JR, Heymes A (1993) Tetrahedron 49:2915–2938

    Article  CAS  Google Scholar 

  98. Bisagni E, Ducrocq C, Lhoste JM, Rivalle C, Civier A (1979) J Chem Soc Perkin Trans 1:1706–1711

    Article  Google Scholar 

  99. Ducrocq C, Wendling F, Tourbez-Perrin M, Rivalle C et al. (1980) J Med Chem 23:1212–1216

    Article  PubMed  CAS  Google Scholar 

  100. Langdon SP, Hendriks HR, Braakhuis BJ, Pratesi G, Berger DP, Fodstad O, Fiebig HH, Boven E (1994) Preclinical phase II studies in human tumor xenografts: a european multicenter follow-up study. Ann Oncol 5(5):415–422

    PubMed  CAS  Google Scholar 

  101. Kattan J, Durand M, Droz JP, Mahjoubi M, Marino JP, Azab M (1994) Phase I study of retelleptine dihydrochloride (SR 95325 B) using a single two-hour intravenous infusion schedule. Am J Clin Oncol 17(3):242–245

    Article  PubMed  CAS  Google Scholar 

  102. ABDA, Pharmazeutische Stoffliste

    Google Scholar 

  103. Deutsch Apoth Ztg (1993) Neue Arzneimittel 10

    Google Scholar 

  104. Desnoyers PC, Samama MM (1995) Pharmakokinetics and metabolism of reviparin. Drugs Today 31(Suppl. D):61–72

    Google Scholar 

  105. Kakkar W, Cohen AT, Mohamed MS (1996) Patients at risk of venous thromboembolism — clinical results with reviparin. Thromb Res 81:39–45

    Article  Google Scholar 

  106. Fareed J, Jeske W, Eschenfelder V, Iqbal O, Hoppensteadt D, Ahsan A (1996) Preclinical studies on a low molecular weight heparin. Thromb Res 81:S1–S27

    Article  PubMed  CAS  Google Scholar 

  107. Klöcking HP (1994) Influence of pentosan polysulfate sodium compared with other polyanion compounds on the t-PA and PAI-1 activity. Perfusion 7(Suppl. 2) 7:32–38

    Google Scholar 

  108. Pindur G, Köhler M, Wenzel E (1989) Study of new low molecular weight heparin (LU 47311) administered to healthy volunteers. Folia Haematol (Leipzig) 116:859–866

    CAS  Google Scholar 

  109. Andrassy K, Eschenfelder V, Koderisch J, Weber E (1994) Pharmacokinetics of Clivarin® a new low molecular weight heparin in healthy volunteers. Thromb Res 73:95–108

    Article  PubMed  CAS  Google Scholar 

  110. Cohen AT, Mohamed MS, Kakkar VV (1995) The clinical experience of reviparin in the prevention of deep vein thrombosis. Drugs Today 31(Suppl.D):5–9

    Google Scholar 

  111. Boneu B (1993) An international multicenter study: Clivarin® in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin® Assesment Group. Blood Coagul Fibrinolysis 4(Suppl.1):S21–S22

    PubMed  Google Scholar 

  112. Kakkar VV (1993) Efficacy and safety of Clivarin® and other LMWHs in general surgery: A meta-analysis. Blood Coagul Fibrinolysis 4(Suppl.1):S23–S27

    PubMed  Google Scholar 

  113. Kakkar VV, Boeckl O, Boneu B, Bordenave L, Brehm OA, Brucke P, Coccheri S, Cohen AT, Galland, Haas S, Jarrige J, Koppenhagen K, Le Querrec A, Parraguette E, Prandoni P, Roder JD, Roos M, Ruschemeyer C, Siewert JR, Vinazzer J, Wenzel E (1997) Efficacy and safety of a low-molecular-weight heaprin and standard unfractionated heparin in prophylaxis of postoperative venous thromboembolism: A Europeen multicenter trial. World J Surg 21:2–8

    Article  PubMed  CAS  Google Scholar 

  114. Planés A (1995) Reviparin in elective hip surgery. Drugs Today 31(Suppl. D):45–48

    Google Scholar 

  115. Planés A, Vochelle N, Chevret S, Fagola M, Bellaud M (1993) Dose-finding studies of reviparin in elective hip surgery. Semin Thromb Haemost 19(Suppl. 1):44–48

    Google Scholar 

  116. Planés A (1993) Comparison of antithrombotic efficacy and haemorrhagic side-effect of Clivarin® versus Enoxaparin in patients undergoing total hip replacement surgery. Blood Coagul Fibrinolysis 4(Suppl.1):S33–S35

    PubMed  Google Scholar 

  117. Preisack M, Karsch KR (1996) Low molecular weight heparin in prevention of restenosis after PTCA. Thromb Res 81(Suppl.2):S53–S59

    Article  PubMed  CAS  Google Scholar 

  118. Karsch KR (1995) Prevention of restenosis after PTCA with reviparin. Drugs Today 31(Suppl.D):49–60

    Google Scholar 

  119. Schmid KM, Preisack M, Voelker W, Sujatta M, Karsch KR (1993) First clinical experience with low molecular weight heparin LU 47311 (Reviparin) for prevention of restenosis after percutaneous transluminal coronary angioplasty. Semin Thromb Haemost 19(Suppl. 1):155–159

    Google Scholar 

  120. Preisack M, Karsch KR (1993) Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty. Blood Coagul Fibrinolysis 4(Suppl.1):S55–S58

    PubMed  CAS  Google Scholar 

  121. Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R (1996) Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of restenosis after PTCA, early administration of reviparin in a double-blind unfractionated heparin and placebo-controlled evaluation. J Am Coll Cardiol 28:1437–1443

    Article  PubMed  CAS  Google Scholar 

  122. Samama MM, Desnoyers PC (1995) Low molecular weight heparins: an overview. Thrombosis 5:95–106

    Google Scholar 

  123. Andrassy K (1993) Low molecular weight heparin and haemodialysis: Neutralisation by protamine chloride. Blood Coagul Fibrinolysis 4(Suppl. 1):S39–S43

    PubMed  Google Scholar 

  124. Baumelou A, Singlas E, Petitclerc T, Desmichels D, Jacobs C, Soria J (1994) Pharmacokinetics of a low molecular weight heparin (reviparine) in haemodialysed patients. Nephron 68:202–205

    Article  PubMed  CAS  Google Scholar 

  125. Kakkar VV (1996) Cost-effectiveness of the low molecular weight heparin reviparin sodium in thromboprophylaxis. Thromb Res 81(Suppl. 2):S75–S77

    Article  PubMed  CAS  Google Scholar 

  126. Andrassy K, Eschenfelder V (1996) Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Thromb Res 81:S29–S38

    Article  PubMed  CAS  Google Scholar 

  127. Frydman A (1996) Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacocinetics and metabolism in humans. Haemostasis 26(Suppl.2):24–38

    PubMed  CAS  Google Scholar 

  128. Andrassy K, Eschenfelder V, Weber E (1994) Neutralisation of the anticoagulant activity of low molecular weight heparin LU 47311 (Clivarin) in man by protamine chloride. Thromb Res 73:85–93

    Article  PubMed  CAS  Google Scholar 

  129. Knoll Investigator’s Brochure Clivarine® (1996) Knoll AG, Ludwigshafen, Edition 7/96,pp13-14

    Google Scholar 

  130. Klöcking HP, Jelinek A, Klöcking R (1998) The cytotoxicity of sulfated carbohydrates with anticoagulated and profibrinolytic properties. Pharm Pharmacol Lett 8:72–74

    Google Scholar 

  131. Csupor L (1971) Arch Pharm 304:32 ff

    Article  CAS  Google Scholar 

  132. Negwer M (1994) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin, S. 8386

    Google Scholar 

  133. Bironsite D, Ollinger K (1997) Chem Biol Interact 103:35–50

    Article  Google Scholar 

  134. Spencer CM, Wilde MI (1997) Drugs 53:98–106

    Article  PubMed  CAS  Google Scholar 

  135. Yael T, Yamauchi K, Kuwano S (1997) J Pharm Pharmacol 49:22–25

    Article  Google Scholar 

  136. Witkowski JT, Robins RK, Sidwell RW, Simon LN (1972) J Med Chem 16:1150–1154

    Article  Google Scholar 

  137. Witkowski JT, Robins RK, Khare GP, Sidwell RW (1973) J Med Chem 16:935–937

    Article  PubMed  CAS  Google Scholar 

  138. Paroni R, Sirtori CR, Borghi C, Galli KM (1987) J Chromatogr 420:189–196

    Article  PubMed  CAS  Google Scholar 

  139. Smith RHA, Gilbert BE (1987) J Chromatogr 414:202–210

    Article  PubMed  CAS  Google Scholar 

  140. Granich GG, Krogstad DJ, Connor JD, Desrochers KL, Sherwood C (1989) Antimicrob Agents Chemother 33:311–315

    Article  PubMed  CAS  Google Scholar 

  141. Hayden FG (1995) Virustatic agents, Ribavirin. In: Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases 4th edition. Churchill Livingstone New York: 430-431

    Google Scholar 

  142. Wray SK, Gilbert BE, Noall MW, Knight V (1985) Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Res 5:29–37

    Article  PubMed  CAS  Google Scholar 

  143. Hall CB, McBride JT, Walsh EE, Bell DM, Gala CL, Hildreth S, Ten Eyck LG, Hall WJ (1983) Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med 308:1443–1447

    Article  PubMed  CAS  Google Scholar 

  144. Groothuis JR, Woodin KA, Katz R, Robertson AD, McBride JT, Hall CB, McWilliams BC, Lauer BA (1990) Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J Pediatr 117:792–798

    Article  PubMed  CAS  Google Scholar 

  145. Smith DW, Frankel LR, Mathers LH, Tang AT, Araigno RL, Prober CG (1991) A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N. Engl. J Med 325:24–29

    CAS  Google Scholar 

  146. NN (1997) Virazole. Informationsmaterial des Herstellers (ICN Pharmaceuticals, D-37269 Eschwege) (Online:http://www.icnpharm.com/pharma/insert.htm)

    Google Scholar 

  147. Connor J (1990) Ribavirin pharmacokinetics. Pediatr Infect Dis J 9(9 Suppl):S91–S92

    PubMed  CAS  Google Scholar 

  148. Fa. Hoffmann-La Roche (1970) Vitamin-Compendium, Basel, S. 98-104

    Google Scholar 

  149. Friedrich W (1987) Handbuch der Vitamine, Urban & Schwarzenberg, München Wien Baltimore, S. 261–304

    Google Scholar 

  150. Pharmeuropa (1994) 6:268-270

    Google Scholar 

  151. Hsu HC (1978) T’ai-wan Yao Hsueh Tsa Chih 30:20–29, zit. nach CA (1979) 90:174583

    CAS  Google Scholar 

  152. Adanyaeva RV, Demisova LY, Borovikova ON, Berezovskii VM (1967) Khim Farm Zh 1:16–19, zit. nach CA (1967) 67:25380

    CAS  Google Scholar 

  153. Maeda Y, Owada K, Yamamoto M, Sano S, Masui T, Kitada Y (1990) Iyakuhin Kenkyu 21:444–448, zit. nach CA (1990) 113:198102

    CAS  Google Scholar 

  154. Mar 31, S. 1383

    Google Scholar 

  155. Schoenen J, Lenaerts M, Bastings E (1994) Cephalgia 14:328–329

    Article  CAS  Google Scholar 

  156. Mar 31, S. 1748

    Google Scholar 

  157. Freyne EJ, Raeymaekers AHM, Venet MG, Sipido VK, De Clerck F (1990) Drug Fut 15:463–466

    Google Scholar 

  158. De Clerck F, Beetens J, de Chaffoy, de Courcelles D, Freyne E, Janssen PA (1989) R68 070: thromboxane A2 synthetase inhibiton und thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule. I. Biochemical profile in vitro. Thromb Haemost 61:35–42

    PubMed  Google Scholar 

  159. De Clerck F, Beetens J, Van de Water A, Vercammen E, Janssen PA (1989) R 86 070: thromboxane A2 synthase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule. II Pharmacological effects in vivo and ex vivo. Thromb Haemost 61:43–49

    PubMed  Google Scholar 

  160. Hoet B, Deckmyn H, Arnout J, Vermylen J (1990) Pharmacological manipulation of the thromboxane pathway in blood platelets. Blood Coagul Fibrinolysis 1:225–233

    PubMed  CAS  Google Scholar 

  161. de Chaffoy de Courcelles D, De Clerck F (1990) Effect of thromboxane A2 synthetase inhibition, single and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets. Eur J Pharmacol 188:161–169

    Article  PubMed  Google Scholar 

  162. Vanden Bossche H, Willemsens G, Bellens D, Janssen PA (1992) Ridogrel: a selective inhibitor of the cytochrome P450-dependent thromboxane synthesis. Biochem Pharmacol 43:739–744

    Article  PubMed  CAS  Google Scholar 

  163. Heylen L, De Clerck F, Somers Y, Leysen JE (1991) Thromboxane A2/prostaglandin endoperoxide (TXA2/ PG-END) receptor binding properties in human platelets of ridogrel, a combined TXA2 synthase inhibitor-TXA2/ PG-END receptor antagonist. Blood Coagul Fibrinolysis 2:617–621

    Article  PubMed  CAS  Google Scholar 

  164. Bourgain RH, Andries R, Decuyper K, De Clerck F (1991) Dual inhibition of thromboxane A2 synthesis and thromboxane A2/prostaglandin endoperoxide receptor by ridogrel: anti-thrombotic effect in vivo in rat mesenteric arteries. J Lipid Mediat 3:3–11

    PubMed  CAS  Google Scholar 

  165. Verheyen A, Lauwers F, Vlaminckx E, De Clerck F (1989) Differential vasoreactivity to the thromboxane A2 mimic U-46619 of collateral and normal peripheral blood vessels in situ perfused rat hindquarters. Blood Vessels 26:165–176

    PubMed  CAS  Google Scholar 

  166. Janssen WJ, Cools FJ, Hoskens LA, Van Nueten JM (1990) Effect of ridogrel on vascular contractions caused by vasoactive substances released during platelet activation. Thromb Haemost 64:91–96

    Google Scholar 

  167. Vandeplassche G, Hermans C, Van de Water A, Xhonneux R, Wouters L, Van Ammel K, De Clerck F (1991) Differential effects of thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries. Circ Res 69:313–324

    Article  PubMed  CAS  Google Scholar 

  168. Vandeplassche G, Hermans C, Somers Y, Van de Werf F, de Clerck F (1993) Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase. J Am Coll Cardiol 21:1269–1279

    Article  PubMed  CAS  Google Scholar 

  169. Hoet B, Arnout J, Vermylen J (1989) R68070, a combined thromboxane/endoperoxide receptor antagonist (TRA) and thromboxane synthase inhibitor (TSI), prolongs the bleeding time more than aspirin in man. Prog Clin Biol Res 301:537–577

    Google Scholar 

  170. Weber C, Beetens JR, Tegtmeier F, Van Rooy P, Vercammen E, Wouters L, De Clerck F (1992) Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration in man. Thromb Haemost 68:214–220

    PubMed  CAS  Google Scholar 

  171. Ritter JM, Barrow SE, Doktor HS, Stratton PD; Edwards JS, Henry JA, Gould S (1993) Thromboxane A2 receptor antagonism and synthase inhibition in essential hypertension. Hypertension 22:197–203

    Article  PubMed  CAS  Google Scholar 

  172. De Cree J, Geukens H, Gutwirth P, De Clerck F, Vercammen E, Verhaegen H (1993) The effect of a combined administration of ridogrel and ketanserin in patients with intermittens claudication. Int Angiol 12:59–68

    PubMed  Google Scholar 

  173. Timmermans C, Vrolix M, Vanhaecke J, Stammen F, Piessens J, Vercammen E, De Geest H (1991) Ridogrel in setting of percutaneous transluminal coronary angioplasty. Am J Cardiol 68:463–466

    Article  PubMed  CAS  Google Scholar 

  174. van der Wieken LR, Simoons ML, Laarman GJ, Van den Brand M, Nijssen KM, Dellborg M, Hermens W, Vrolik W (1995) Ridogrel as an adjunct to thrombolysis on acute myocardial infarction. Int J Cardiol 52:125–134

    Article  PubMed  Google Scholar 

  175. Tranchesi B, Pileggi F, Vercammen E, Van de Werf F, Verstraeten M (1994) Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin. Eur Heart J 15:660–664

    PubMed  CAS  Google Scholar 

  176. Cricchio R, Arioli V (1976) Ger Offen 2,608,218; zit. nach CA 86:43757

    Google Scholar 

  177. Riva E, Merati R, Cavenaghi L (1991) J Chromatogr 553:35–40

    Article  PubMed  CAS  Google Scholar 

  178. Vékey K, Edwards DMF, Zerilli LF (1989) J Chromatogr 474:317–327

    Article  PubMed  Google Scholar 

  179. Marchi E, Montecchi L, Venturini AP, Mascellani G, Brufani M, Cellai L (1985) J Med Chem 28:960–963

    Article  PubMed  CAS  Google Scholar 

  180. Dampier MF, Chen CW, Whitlock HW (1976) J Am Chem Soc 98:7064–7069

    Article  PubMed  CAS  Google Scholar 

  181. Bellomo P, Marchi E, Mascellini G (1981) J Med Chem 24:1310–1314

    Article  PubMed  CAS  Google Scholar 

  182. Corti P, Savini L, Celesti L, Ceramelli G, Montecchi L (1992) Pharm Helv Acta 67:76–79

    CAS  Google Scholar 

  183. Gillis JC, Brogden RN (1995) Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 49:467–484

    Article  PubMed  CAS  Google Scholar 

  184. Drugs Fut (1986) 11(6):470-471

    Google Scholar 

  185. Bousquet P (1995) Imidazoline receptors: from basic concepts to recent development. J Cardiovasc Pharmacol 26(Suppl 2):S1–S6

    PubMed  CAS  Google Scholar 

  186. van Zwieten PA (1995) Central imidazoline receptors as a target for centrally acting antihypertensive drugs. Pharm World Sci 17:186–190

    Article  PubMed  Google Scholar 

  187. Head GA (1995) Importance of imidazoline receptors in the cardiovascular actions of centrally acting antihypertensive agents. Ann NY Acad Sci 763:531–540

    Article  PubMed  CAS  Google Scholar 

  188. Schafer SG, Kaan EC, Christen MO, Low Kroger A, et al. (1995) Why imidazoline receptor modulator in the treatment of hypertension? Ann NY Acad Sci 763:659–672

    Article  PubMed  CAS  Google Scholar 

  189. Boucher M, Dubar M, Chassaing C, Vivet P, et al. (1994) Cardiac electrophysiological effects of rilmenidine, a novel antihypertensive agent, in the conscious dog: comparison with clonidine. Life Sci 54:PL381–PL387

    Article  PubMed  CAS  Google Scholar 

  190. Szabo B, Urban R (1995) Mechanism of sympathoinhibition by imidazolines. Ann NY Acad Sci 763:552–565

    Article  PubMed  CAS  Google Scholar 

  191. Hauser W, Gutting J, Nguyen T, Dominiak P (1995) Influence of imidazolines on catecholamine release in pithed spontaneously hypertensive rats. Ann NY Acad Sci 763:573–579

    Article  PubMed  CAS  Google Scholar 

  192. Gargalidis Moudanos C, Parini A (1995) Selectivity of rilmenidine for Il-imidiazoline-binding sites in rabbit proximal tubule cells. J Cardiovasc Pharmacol 26(Suppl 2):S59–S62

    PubMed  CAS  Google Scholar 

  193. Kline RL, van der Mark J, Cechetto DF (1994) Natriuretic effect of rilmenidine in anesthetized rats. Am J Cardiol 74:20A–24A

    Article  PubMed  CAS  Google Scholar 

  194. Evans RG, Anderson WP (1995) Renal effects of infusion of rilmenidine and guanabenz in conscious dogs: contribution of peripheral and central nervous system alpha 2-adrenoceptors. Br J Pharmacol 116:1557–1570

    Article  PubMed  CAS  Google Scholar 

  195. Fletcher AE, Beevers DG, Dollery CT, Wilkinson R, et al. (1991) The effects of two centrally-acting anti-hypertensive drugs on the quality of life. Eur J Clin Pharmacol 41:397–400

    Article  PubMed  CAS  Google Scholar 

  196. Pillion G, Fevrier B, Codis P, Schutz D (1994) Long-term control of blood pressure by rilmenidine in high-risk populations. Am J Cardiol 74:58A–65A

    Article  PubMed  CAS  Google Scholar 

  197. Licata G, Scaglione R, Guillet C, Capuana G, et al. (1993) Double-blind controlled study of rilmenidine versus hydrochlorothiazide in mild hypertension: clinical and renal haemodynamic evaluation. J Hum Hypertens 7:153–157

    PubMed  CAS  Google Scholar 

  198. Luccioni R (1995) Evaluation pharmaco-epidemiologique de la rilmenidine chez 18235 hypertendus. Presse Med 24:1857–1864

    PubMed  CAS  Google Scholar 

  199. Fiorentini C, Guillet C, Guazzi M (1989) Étude multicentrique en double aveugle comparant la rilmenidine 1 mg et l’hydrochlorothiazide 25 mg chez 244 patients. Arch Mal Coeur Vaiss 82:39–46

    PubMed  Google Scholar 

  200. Trimarco B, Morisco C, Sarno D, Lovino G, et al. (1995) Rilmenidine in patients with left ventricular hypertrophy: beyond the reduction of left ventricular mass. J Cardiovasc Pharmacol 26(Suppl 2):S29–S33

    PubMed  CAS  Google Scholar 

  201. Pelemans W, Verhaeghe J, Creytens G, Coupez G, et al. (1994) Efficacy and safety of rilmenidine in elderly patients — comparison with hydrochlorothiazide. The Belgian Multicentre Study Group. Am J Cardiol 74:51A–57A

    Article  PubMed  CAS  Google Scholar 

  202. Genissel P, Bromet N (1989) Pharmacokinetics of rilmenidine. Am J Med 87:18S–23S

    Article  PubMed  CAS  Google Scholar 

  203. Aparicio M, Dratwa M, el Esper N, Fillastre JP, et al. (1994) Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients. Am J Cardiol 74:43A–50A

    Article  PubMed  CAS  Google Scholar 

  204. Krentz AJ, Evans AJ (1998) Selective imidazoline receptor agonists for metabolic syndrome. Lancet 351:152–153

    Article  PubMed  CAS  Google Scholar 

  205. Lins RL, Daelemans R, Dratwa M, Verbeelen D, et al. (1989) Acceptability of rilmenidine and long term surveillance of plasma concentrations in hypertensive patients with renal insufficiency. Am J Med 87:41S–45S

    Article  PubMed  CAS  Google Scholar 

  206. Braga PC, Dal Sasso M, Maci S, Piatti G, Dannhorn DR, Bohn M (1995) Arzneim-Forsch/Drug Res 45(I):84–87

    CAS  Google Scholar 

  207. Raether W, Hänel H (1990) Rilopirox — a new hydroxypyridone antifungal with fungicidal properties. Mycoses 33:191–202

    PubMed  CAS  Google Scholar 

  208. Drugs Fut (1994) 19:920-922

    Google Scholar 

  209. Jimonet P, Audiau P, Barreau M, Mignani S (1993) Heterocycl 36:2745–2752

    Article  CAS  Google Scholar 

  210. Produktmonographie der Fa. Rhone-Poulenc Rorer

    Google Scholar 

  211. Bensimon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. New Engl J Med 330:585–691

    Article  PubMed  CAS  Google Scholar 

  212. Couratier P, Sindou P, Esclaire F, Louvel E, Hugon J (1994) Neuroprotective effects of riluzole in ALS CSF toxicity. Neuroreport. 5:1012–1014

    Article  PubMed  CAS  Google Scholar 

  213. Doble A, Hubert JP, Blanchard JC (1992) Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on D-(3H)aspartate release from cultured cerebellar granule cells. Neuroscience Letters. 140:251–254

    Article  PubMed  CAS  Google Scholar 

  214. Hubert JP, Delumeau JC, Glowinski J, Premont J, Doble A (1994) Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action. Brit J Pharmacol. 113:261–267

    Article  CAS  Google Scholar 

  215. Rowland LP (1994) Amyotrophic lateral sclerosis. Current Opinion in Neurology. 7:310–315

    Article  PubMed  CAS  Google Scholar 

  216. Samuel D, Blin O, Dusticier N, Nieoullon A (1992) Effects of riluzole (2-amino-6-trifluoromethoxy benzothiazole) on striatal neurochemical markers in the rat, with special reference to the dopamine, choline, GABA and glutamate synaptosomal high affinity. Fundam Clin Pharmacol 6:177–184

    Article  PubMed  CAS  Google Scholar 

  217. Benedict JJ, Perkins CM; AU 85513534, EP 186405, ES 8707543 (1993) Drugs Fut 18(7):605-608

    Google Scholar 

  218. Wellcome Foundation Ltd. Jap Pat 8064585; zit. nach CA (1985) 94:4042

    Google Scholar 

  219. Vitté C, Fleisch H, Guenther HL (1996) Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137:2324–2333

    Article  PubMed  Google Scholar 

  220. Fleisch H (1991) Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42:919–944

    Article  PubMed  CAS  Google Scholar 

  221. Roux C, Ravaud P, Cohen-Solal M (1994) Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 15:41–49

    Article  PubMed  CAS  Google Scholar 

  222. Brown HP, Kylstra JW, Bekker PJ (1994) Risedronate in Paget’s disease: preliminary results of a multicenter study. Sem Arthritis Rheum 23:272

    Article  CAS  Google Scholar 

  223. Delmas PD, Balena R, Confravreux E (1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind placebo-controlled study. J Clin Oncol 15:955–962

    PubMed  CAS  Google Scholar 

  224. Reasner CA, Stone MD, Hosking DJ (1993) Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. Clin Endocrinol Metab 77:067–1071

    Google Scholar 

  225. Watts NB (1994) Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am 20:717–734

    PubMed  CAS  Google Scholar 

  226. Fleisch H (1994) Bisphosphonates: pharmacology. Sem Arthritis Rheum 23:261–262

    Article  CAS  Google Scholar 

  227. Kennis LEJ, Vandenberk J (1986) Eur Pat Appl EP 196132, zit. nach CA (1987) 160:67292x

    Google Scholar 

  228. Woestenborghs R, Lorreyne W, van Rompaey F (1992) J Chromatogr 582:223–230

    Google Scholar 

  229. le Moing JP, Edouard S, Levron JC (1993) J Chromatogr 614:333–339

    Article  PubMed  Google Scholar 

  230. Buckley PF (1997) New dimensions in the pharmacological treatment of schizophrenia and related psychoses. J Clin Pharmacol 37:363–378

    Article  PubMed  CAS  Google Scholar 

  231. Jacobsen FM (1995) Risperidone in the treatment of affective illness and obsessive — compulsive disorder. J Clin Psychiat 56:423–429

    CAS  Google Scholar 

  232. Kerwin R, Taylor D (1996) New Antipsychotics. A review of their current status and clinical potential. CNS Drugs 6:71–82

    Article  CAS  Google Scholar 

  233. Umbricht D, Kane JM (1996) Medical complications of new antipsychotic drugs. Schizophrenia Bull 22:475–483

    Article  CAS  Google Scholar 

  234. Peuskens J (1995) Risperidon in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Brit J Psychiat 166:712–733

    Article  PubMed  CAS  Google Scholar 

  235. Drugs Fut (1986) 11(5):391-393

    Google Scholar 

  236. Marsden CA (1990) The pharmacology of new anxiolytics acting on 5-HT neurones. Postgrad Med J 66(Suppl 2):S2–S6

    PubMed  CAS  Google Scholar 

  237. Bersani G (1991) 5-HT2-receptor antagonism in dystymic disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatr Scand 83:244–248

    Article  PubMed  CAS  Google Scholar 

  238. Wagner B, Schneider B, Blöchl-Daum B, Speiser W, et al. (1990) Effect of ritanserin, a 5-hydroxytryptamine2-receptor antagonist, on platelet function and thrombin generation at the site of plug formation in vivo. Clin Pharmacol Ther 48:419–423

    Article  PubMed  CAS  Google Scholar 

  239. Stott DJ, Saniabadi AR, Lowe GDO, Ball SG (1988) The effects of the 5-HT2-antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension. Eur J Clin Pharmacol 35:132–129

    Google Scholar 

  240. Bedeschi A, Cabri W, Marchi M, Perrone E (Farmitalia Carlo Erba) GB 9006114.4; zit. nach Drugs Fut (1991) 16:313-316

    Google Scholar 

  241. Battistini C, Scarafile C, Foglio M, Franceschi G (1984) Tetrahedron Lett 25:2395–2398

    Article  CAS  Google Scholar 

  242. Altamura M, Cesti P, Francalanci F, Marchi M, Cambiaghi S (1989) J Chem Soc Perkin Trans I, 1225–1229

    Article  Google Scholar 

  243. Franceschi g, Bedeschi A, Rizzo V, Vigevanni A (1993) Bioorg Med Chem Lett 3:2333–2336

    Article  CAS  Google Scholar 

  244. Efthymiopoulos C, Strolin Benedetti M, Sassella D, Boobis A, Davies D (1992) Antimicrob Ag Chemother 36(9):1958–1963

    Article  CAS  Google Scholar 

  245. Saathoff A, Lode H, Hampel B, Deppermann KM, Borner K, Koeppe P (1990) Antimicrob Ag Chemother 34(6):1001–1006

    Article  CAS  Google Scholar 

  246. Boersma WG, Puister SMT, van Altena R, de Vries-Hospers HG, Molinari M, Koeter GH (1994) Antimicrob Ag Chemother 38(4):872–875

    Article  CAS  Google Scholar 

  247. Norrby SR, Dornbusch K, Molinari M, Sassella D, Atti E, Gefvert O, Zador R, Petroccione A, Cairoli C, Fransson G, Denstedt-Stigzelius I, Bakall A, Olsson E, Wiberg PO, Babra M, Gaseb M, Pavek E, Johansson S, Bergstad B, von Kraemer S, Thorell NI, Grundestam I, Forsberg G, Almqvist G, Tilling B, Gnarpe H, Schwan A, Sörén L (1995) Clin Infect Dis 20:507–513

    Article  Google Scholar 

  248. Livingstone D, Gill MJ, Wise R (1995) J Antimicrob Chemother 35(1):1–5

    Article  PubMed  CAS  Google Scholar 

  249. Norrby SR, Burman LA, Sassella D, Corigli R, Cassinelli G, Franceschi G, Dornbusch K (1990) J Antimicrob Chemother 25:371–383

    Article  PubMed  CAS  Google Scholar 

  250. Lovering AM, MacGowan AP, Lewis DH, Reeves DS (1992) J Antimicrob Chemother 29:179–185

    Article  PubMed  CAS  Google Scholar 

  251. Webberley JM, Wise R, Andrews JM, Ashby JP, Wallbridge D (1988) J Antimicrob Chemother 21:445–450

    Article  PubMed  CAS  Google Scholar 

  252. Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE (1992) Clin Infect Dis 15(Suppl 1):216–227

    Article  Google Scholar 

  253. Saito A, Kawakami Y, Yamaguchi E, Koba H, Abe S, Ohmichi M, Hiraga Y, Kikuchi K, Ohsaki Y, Matsumoto H, Inoue H, Yoshida M, Mouri T, Kobayashi H, Ito T, Bando T, Takeuchi K, Hirano H, Tanifuji Y, Tanno Y, Kirato K, Takahashi M, Sakamoi M, Nakashima M; et al. (1996) Jap J Antibiotics 49(3):219–249

    CAS  Google Scholar 

  254. NN (1993) Drugs Fut 18:373

    Google Scholar 

  255. Angerbauer R, Fey P, Hübsch W, Philipps T, Bischoff H, Petzinna D, Schmidt D, Thomas G (Bayer AG) EP 325139, US 5006530, US 5169857 und Angerbauer R, Fey P, Hübsch W, Philipps T, Bischoff H, Petzinna D, Schmidt D, Thomas G (Bayer AG) EP 491226, US 5177080; beide zit. nach Lit. 2

    Google Scholar 

  256. Angerbauer R, Bischoff H, Steinke W, Ritter W (1994) Drugs Fut 19:537–541

    Google Scholar 

  257. Angerbauer R, Bischoff H, Bömer B, Fey P, Grosser R, Hübsch W, Lange W, Lautz J, Schmidt D (1993) 2te Eur Med Chem Conf (31. März bis 4. April, Bad Nauheim); zit. nach Lit. 2

    Google Scholar 

  258. Ness GC, Zhao Z, Lopez D (1996) Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch Biochem Biophys 325:242–248

    Article  PubMed  CAS  Google Scholar 

  259. Gargouri Y, Pieroni G, Riviere C, Sauniere JF, Lowe PA, Sarda L, Verger R (1986) Gastroenterology 91:919–925

    PubMed  CAS  Google Scholar 

  260. Swan JS, Hoffmann MM, Lord MK, Poechmann JL (1992) Biochem J 283:119–122

    PubMed  CAS  Google Scholar 

  261. Walde P, Luisi PL (1989) Biochem 28:3353–3360

    Article  CAS  Google Scholar 

  262. Möller H (1979) Dtsch Apoth Ztg 124:2279–2286

    Google Scholar 

  263. Bergmeyer HU (1983) Methods of Enzymatic Analysis, 3.Aufl., Bd.2, Verlag Chemie, Weinheim, S. 236

    Google Scholar 

  264. Junge W (1984) Lipasen in: Bergmeyer HU (Hrsg), 3. Aufl., Bd.4, Verlag Chemie, Weinheim, S. 15–25

    Google Scholar 

  265. Pointner H, Flegel U (1975) Arzneim Forsch 25:1833–1835

    CAS  Google Scholar 

  266. Unterberg C, Spencer F (1986) Fette Seifen Anstrichmittel 88:561–564

    Article  Google Scholar 

  267. Ammann R (1979) Internist 20:392–398

    PubMed  CAS  Google Scholar 

  268. DiMagno EP, Go VLW, Summerskill WHJ (1973) N Engl J Med 288:813–815

    Article  PubMed  CAS  Google Scholar 

  269. Löser Chr, Fölsch UR (1991) Leber Magen Darm, Heft 2:56–65

    Google Scholar 

  270. Abiodun P, Tolckmitt W (1982) Der Kinderarzt 13:1987–1994

    Google Scholar 

  271. Brackmann P, Rüther HG (1984) Fortschr med 44:102, 1143/1165-145/167

    Google Scholar 

  272. Fölsch UR (1989) Dtsch Ärztebl 86:792–793

    Google Scholar 

  273. Drugs Fut (1994) 19(9):841-844, zit. nach Savage DS, Sleig T, Carlyte IG; AU 8814570, EP 297150, JP 88277693, US 4894369

    Google Scholar 

  274. Mirakhur RK (1992) Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use. Drugs 44:182–199

    Article  PubMed  CAS  Google Scholar 

  275. Mellinghoff H (1994) Moderne Muskelrelaxanzien und ihre klinische Anwendung. Anaesthesist 43:270–282

    Article  PubMed  CAS  Google Scholar 

  276. Bevan DT (1994) Newer neuromuscular blocking agents. Pharmacol Toxicol 74:3–9

    Article  PubMed  CAS  Google Scholar 

  277. Caldwell JE (1995) New skeletal muscle relaxants. Int Anesthesiol Clin 33:39–60

    Article  PubMed  CAS  Google Scholar 

  278. Hunter JM (1995) New neuromuscular blocking drugs. N Engl. J Med 332:1691–1699

    Article  PubMed  CAS  Google Scholar 

  279. Appadu BL, Lambert DG (1994) Studies on the interaction of steroidal neuromuscular blocking drugs with cardiac muscarine receptors. Br J Anaesth 72:86–88

    Article  PubMed  CAS  Google Scholar 

  280. Naguib M, Samarkandi AH, Bakhamees HS, Magboul MA, el Bakry AK (1995) Histamine-release and haemodynamic changes produced by rocuronium, vecuronium, mivacurium, atracurium and tubocurarine. Br J Anaesth 75:588–592

    Article  PubMed  CAS  Google Scholar 

  281. McCoy EP, Mirakhur RK, Maddineni VR, Wierda JM, Proost JH (1996) Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. Br J Anaesth 76:29–33

    Article  PubMed  CAS  Google Scholar 

  282. Sparr HJ, Khuenl-Brady KS, Eriksson LI (1994) Pharmacodynamics and pharmacokinetics of rocuronium following continuous infusion in patients during intravenous anaesthesia. Eur J Anaesthesiol Suppl 9:63–65

    PubMed  CAS  Google Scholar 

  283. Mar 31, S.1525

    Google Scholar 

  284. Diefenbach C (1997) Mivacurium und Cisatracurium. Arzneimitteltherapie 15:65–68

    Google Scholar 

  285. Cooper RA, Mirakhur RK, Wierda JM, Maddineni VR (1995) Pharmacokinetics of rocuronium bromide in patients with and without renal failure. Eur J Anaesthesiol Suppl 11:43–44

    PubMed  CAS  Google Scholar 

  286. van den Broek L, Wierda JM, Smeulers NJ, van Santen GJ, Leclercq MG, Hennis PJ (1994) Clinical pharmacology of rocuronium (Org 9426): study of the time course of action, dose requirement, reversibility, and pharmacokinetics. J Clin Anesth 6:288–296

    Article  PubMed  Google Scholar 

  287. Khalil M, D’Honneur G, Duvaldestin P, Slavor V (1994) Pharmacokinetics and pharmacodynamics in patients with cirrhosis. Anaesthesiology 80:1241–1247

    Article  CAS  Google Scholar 

  288. Bevan DR (1994) Rocuronium bromide and organ function. Eur J Anaesthesiol Suppl 9:87–91

    PubMed  CAS  Google Scholar 

  289. Mirakhur RK (1995) Dose-response and time-course of action of rocuronium bromide. Eur J Anaesthesiol Suppl 11:23–25

    PubMed  CAS  Google Scholar 

  290. Mayer M, Doenicke A, Hofmann A, Peter K (1992) Onset and recovery of rocuronium (Org 9426) and vecuronium under enflurane anaesthesia. Br J Anaesth 69:511–512

    Article  PubMed  CAS  Google Scholar 

  291. Khuenl-Brady KS (1993) Rocuronium, das „ideale“ nicht depolarisierende Muskelrelaxans? Anaesthesist 42:757–765

    PubMed  CAS  Google Scholar 

  292. Scheiber G, Ribeiro FC, Marichal A, Bredendiek M, Renzing K (1996) Intubating conditions and onset of action after rocuronium, vecuronium, and atracurium in young children. Anesth Analg 83:320–324

    PubMed  CAS  Google Scholar 

  293. Drugs Fut (1992) 17:791-795

    Google Scholar 

  294. McCague F, Jarman M, Rowland MG, Mann J, Thickitt CP, Clissold DW, Neidle S, Webster G (1989) J Chem Soc Perkin Trans I:196

    Article  Google Scholar 

  295. Boss AM, Clissold DW, Mann J, Markson AJ, Thickitt CP (1989) Tetrahedron 45:6011

    Article  CAS  Google Scholar 

  296. Foster AB, Jarman M, Leung C-S, Rowlands MG, Taylor G., Plevey RG, Sampson P (1985) J Med Chem 28:200–204

    Article  PubMed  CAS  Google Scholar 

  297. Lonning PE, Dowsett M, Powles TJ (1990) Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem 35(3–4):355–366

    Article  PubMed  CAS  Google Scholar 

  298. Dowsett M (1990) Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer. J Steroid Biochem Mol Biol 37(6):1037–1041

    Article  PubMed  CAS  Google Scholar 

  299. Hynes BP, Jarman M, Dowsett M, Metha A, Lonning PE, Griggs LJ, Jones A, Powles T Stein R, Coombes RC (1991) Pharmacokineties and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl) piperidine-2,6-dione in patients with postmenopausal breast cancer. Cancer Chemother Pharmacol 27(5):367–372

    Article  Google Scholar 

  300. Dowsett M, MacNeill F, Metha A, Newton C, Haynes B, Jones A, Jarman M, Lonning P, Powles TJ, Coombes RC (1991) Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl) piperidine-2,6-dione (‘pyridoglutethimide’) in postmenopausal breast cancer patients. Br J Cancer 64(5):887–894

    Article  PubMed  CAS  Google Scholar 

  301. Drugs Fut (1993) 18(1):89-89

    Google Scholar 

  302. Drugs Fut (1994) 19(1):83-85

    Google Scholar 

  303. Krause W, Kühne G (1992) J Chromatogr Biomed Appl 573(2):303–308

    Article  CAS  Google Scholar 

  304. Araki T, Kato H, Shuto K, et al (1997) Age-realted changes in (3H)nimodipine and (3H)rolipram binding in the rat brain. J Pharm Pharmacol 49:310–314

    Article  PubMed  CAS  Google Scholar 

  305. Block F, Tondar A, Schmidt W, et al. (1997) Delayed treatment with rolipram protects against neuronal damage following global ischemia in rats. Neuroreport 8:3829–3832

    Article  PubMed  CAS  Google Scholar 

  306. Christensen SB, Guider A, Forster CJ, et al. (1998) 1,4-Cyclohecanecarboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. J Med Chem 41:821–835

    Article  PubMed  CAS  Google Scholar 

  307. Dowling RMB, Johnson M, Cole PJ, et al. (1997) The effect of rolipram, a type IV phosphodiesterase inhibitor, on Pseudomonas aeruginosa infection of respiratory mucosa. J Pharmacol Exp Ther 282:1565–1571

    PubMed  CAS  Google Scholar 

  308. Egawa T, Mishima K, Matsumoto Y, et al. (1997) Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats. Jpn J Pharmacol 75:275–281

    Article  PubMed  CAS  Google Scholar 

  309. Hadcraft J, Hill S, Humpel M, et al. (1990) Investigations on the percutaneous absorption of the antidepressant rolipram in vitro and in vivo. Pharm Res 7:1307–1312

    Article  Google Scholar 

  310. Hasko G, Szabo C, Nemeth ZH, et al. (1998) Suppression of IL-12 production by phosphodiesterase inhibition in murine endotoxemia is IL-10 dependent. Eur J Immunol 28:468–472

    Article  PubMed  CAS  Google Scholar 

  311. Imanishi T, Sawa A, Ichimaru Y, et al. (1997) Ameliorating effects of rolipram on experimentally induced impariment of learning and memory in rodents. Eur J Pharmacol 321:273–278

    Article  PubMed  CAS  Google Scholar 

  312. Krause W, Kuhne G, Matthes H (1989) Pharmacokinetics of the antidepressant rolipram in healthy volunteers. Xenobiotica 19:683–692

    Article  PubMed  CAS  Google Scholar 

  313. Krause W, Kuhne G, Sauerbrey N (1990) Pharmacokinetics of (+)-rolipram and (-)-rolipram in healthy volunteers. Eur J Pharmacol 38:71–75

    Article  CAS  Google Scholar 

  314. Krause W, Kuhne G (1993) Biotransformation of the antidepressant D,L-rolipram. II. Metabolite patterns in man, rat, rabbit, rhesus and cynomolgus monkey. Xenobiotica 23:1277–1288

    Article  PubMed  CAS  Google Scholar 

  315. Liang L, Beshay E, Prud’homme GJ (1998) The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. Diabetes 47:570–575

    Article  PubMed  CAS  Google Scholar 

  316. Navarro J, Punzon C, Jimenez JL, et al. (1998) Inhibition of phosphodiesterase type IV supresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappa B and NFAT. J Virol 72:4712–4720

    PubMed  CAS  Google Scholar 

  317. Nyman U, Mussener A, Larsson E, et al. (1997) Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor rolipram. Clin Exp Immunol 108:415–419

    Article  PubMed  CAS  Google Scholar 

  318. Pfeffer M, Sauerbrey N, Windt-Hanke F, et al. (1990) In-vitro and in-vivo characterisation of two sustained release formulations for the antidepressant rolipram. Arzneimittelf 40:1191–1194

    CAS  Google Scholar 

  319. Ross SE, Williams RO, Mason LJ, et al. (1997) Supression of TNF-alpha expression, inhibition of Th 1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol 159:6253–6259

    PubMed  CAS  Google Scholar 

  320. Saito T, Ozawa H, Kamata H, et al. (1998) Differential effects of chronic administration of the antidepressants amitriptyline and rolipram on adenylyl cyclase activity. Nihon Shinkei Seishin Yakurigaku Zasshi 18:23–25

    PubMed  CAS  Google Scholar 

  321. Shichijo M, Shimizu Y, Hiramatsu K, et al. (1997) Cyclic AMP-elevating agents inhibit mice-antigen-induced IL-4 and IL-13 relase from basophil-enriched leukocyte preparation. Int Arch Allerg Immunol 114:348–353

    Article  CAS  Google Scholar 

  322. Wagner RS, Smith CJ, Taylor AM, et al (1997) Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries. J Pharmacol Exp Ther 282:1650–1657

    PubMed  CAS  Google Scholar 

  323. Yoshimura T, Nagao T, Nakao T, et al (1998) Modulation of Th1-and Th2-like cytokine production from mitogenstimulated human peripheral blood mononuclear cells by phosphodiesterase inhibitors. Gen Pharmacol 30:175–180

    Article  PubMed  CAS  Google Scholar 

  324. Drugs Fut (1989) 14:432-437

    Google Scholar 

  325. Moroi R, Yamazaki K, Hirota T, Watanabe S, Kataoka K, Ichinose M (1988) Arzneim-Forsch 38:953–959

    CAS  Google Scholar 

  326. MI 12

    Google Scholar 

  327. Akasaki M, Masayasu H, Tsukada W et al. (1988) Specific binding sites of muroctasin on murine macrophages. Arznf 38:978–980

    CAS  Google Scholar 

  328. Azuma I (1992) Development of the cytokine inducer romurtide: experimental studies and clinical application. Trends Pharmacol Sci 13:425–428

    Article  PubMed  CAS  Google Scholar 

  329. Azuma I, Ishihara C, Iida J et al. (1992) Stimulation of host-defense mechanism with synthetic adjuvants and re-combinant cytokines against viral infection in mice. Adv Exp Med Biol 319:253–263

    Article  PubMed  CAS  Google Scholar 

  330. Eizuru Y, Nakagawa N, Hamasuna R et al. (1992) Protective effect of MDP-Lys(L18), a synthetic derivative of muramyldipeptide, on murine cytomegalovirus infection. Nat Immun 11:225–236

    PubMed  CAS  Google Scholar 

  331. Furuse K et al. (1989) Prog Med 9:631–649 zit. nach2

    Google Scholar 

  332. Furuse K, Sakuma A (1989) Activation of the cytokine network by muroctasin as a remedy for leukopenia and thrombopenia. Arznf 39:915–917

    CAS  Google Scholar 

  333. Hiraoka A, Masaoka T, Satoh T et al. (1988) Hematological response of the new synthetic muramyl dipeptide derivative muroctasin after chemotherapy in patients with malignant lymphoma. A randomized crossover trial. Arznf 38:1499–1501

    CAS  Google Scholar 

  334. Ishihara N, Kanazawa R, Sasaki S et al. (1988) Phase I study and clinical pharmacological study of muroctasin. Arznf 38:1043–1069

    Google Scholar 

  335. Matsubayashi K, Takegoshi T (1988) Biotransformation of muroctasin in mice. Arznf 38:1015–1018

    CAS  Google Scholar 

  336. Nakajima R, Yshida Y, Akahane K et al. (1991) Stimulatory effect of romurtide on hematopoiesis in monkeys. Arznf 41:60–65

    CAS  Google Scholar 

  337. Nakajima R, Namba K, Ishida Y et al. (1992) Synergistic effect of romurtide with ampicillin against pneumococcal pneumonia in mice. Chemother 38:238–250

    Article  CAS  Google Scholar 

  338. Namba K, Nakajima R, Otani T et al. (1996) Oral application of romurtide, a synthetic muramyl dipeptide derivative, stimulates nonspecific resistance to microbial dipeptide derivative, stimulates nonspecific resistance to microbial infections and hematopoiesis in mice. Vaccine 14:1149–1153

    Article  PubMed  CAS  Google Scholar 

  339. Namba K, Nitanai H, Otani T et al. (1996) Romurtide, a synthetic muramyl dipeptide derivative, accelerates peripheral platelet recovery in nonhuman primate chemotherapy model. Vaccine 14:1322–1326

    Article  PubMed  CAS  Google Scholar 

  340. Namba K, Yamamura E, Nitanai H et al. (1997) Romurtide, a synthetic muramyl dipeptide derivative, promotes megakaryocytopoiesis through stimulation of cytokine production in nonhuman primates with myelosuppression. Vaccine 15:405–413

    Article  PubMed  CAS  Google Scholar 

  341. Osada Y, Otani T, Sato M et al. (1982) Polymorphonuclear leukocyte activation by a synthetic muramyl dipeptide analog. Infect Immun 38:848–854

    PubMed  CAS  Google Scholar 

  342. Suzuki K, Torii K, Hida S et al. (1994) Differences in interleukin 1 (IL-1), IL-6, tumor necrosis factor and IL-1 receptor antagonist production by human monocytes stimulated with muramyl dipeptide (MDP) and its stearoyl derivative, romurtide. Immunopharmacol 28:31–38

    Article  CAS  Google Scholar 

  343. Tatara O, Nakahama C, Niki Y (1992) Synergistic effects of romurtide and cefmenoxime against experimental Klebsiella pneumonia in mice. Antimicrob Ag Chemother 36:167–171

    Article  CAS  Google Scholar 

  344. Tsubura E, Nomura T, Niitani H et al. (1988) Restorative activity of muroctasin on leukopenia associated with anti-cancer treatment. Arznf 38:1070–1074

    CAS  Google Scholar 

  345. Yano K, Matsuoka H, Seo Y et al. (1995) Restorative effect of romurtide for thrombocytopenia associated with intensive anticancer drug treatment and/or irradiation in patients with gastrointestinal cancer. Anticancer Res 15:2883–2887

    PubMed  CAS  Google Scholar 

  346. Yoo YC, Sakai I, Sato K et al. (1994) MDP-Lys (L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice. Vaccine 12:175–160

    Article  PubMed  CAS  Google Scholar 

  347. Drugs Fut (1989) 14(8):767-771

    Google Scholar 

  348. Thuresson Af Ekenstam B, Bovin C (Astra Lakemedel AB), L-N-Propylpipecolic acid-2,6-xylidid. US 4695576; zit. nach1

    Google Scholar 

  349. Thuresson Af Ekenstam B, Bovin C (Apothekernes laboratorium for specialpraeparater A (S). L-N-n-Propylpipecolic acid-2,6-xylidid and method for preparing the same. AU 8317796; EP 151110; JP 855020554; WO 8500599; zit. nach1

    Google Scholar 

  350. Stahlberg C (1987) Synthesis of carbon-14 labelled ropivacaine, a local anaesthetic. J Label Compound Radiopharm 24(5):529–534; zit. nach1

    Article  Google Scholar 

  351. Sandberg RV (Astra Läkemedel Aktiebolag) S-(-)-1-Propyl-2′,6′-pipecoloxylidide hydrochloride monohydrate, process for its preparation and pharmaceutical preparation containing it. EP 239710; zit. nach1

    Google Scholar 

  352. Niesei HC, Kaiser H, Ellingsfeld T (1990) Ropivacain — ein neues Lokalanästhetikum mit spezifischen Eigenschaften. Reg Anaesth 13:54–56

    Google Scholar 

  353. Hickey R, Blanchard J, Hoffman J, Sjovall J, Ramamurthy S (1990) Plasma concentration of ropivacaine given with or without epinephrine for brachia plexus block. Can J Anaesth 8:878–882

    Google Scholar 

  354. March CR, Hardy AJ (1991) Ropivacaine: a new local anaesthetic agent. Br J Hosp Med 45:94–95

    Google Scholar 

  355. Finucane BT (1990) Ropivacaine — a worthy replacement for bupivacaine? Can J Anaesth 37:722–725

    Article  PubMed  CAS  Google Scholar 

  356. Concepcion M, Arthur GR, Steele SM, BaderAM, Covino BG (1990) A new local anaesthetic, ropivacaine. Its epidural effect in humans. Anesth Analg 70:80–85

    Article  PubMed  CAS  Google Scholar 

  357. Zaric D, Axelsson K, Nydahl PA, Philipsson L, Larsson P, Jansson JR (1991) Sensory and motor blockade during epidural analgesia with 1 %, 0,75 %, and 0,5 % ropivacaine — a double blind study. Anesth Analg 72:509–515

    Article  PubMed  CAS  Google Scholar 

  358. Markham A, Faulds D, Abernethy DR, (1996) Ropivacaine. A review of its pharmacology and therapeutic use in regional anaesthesia. Drugs 52:429–449

    Article  PubMed  CAS  Google Scholar 

  359. Lee A, Fagan D, Lamont M, Tucker GT, Halldin M, Scott DB (1989) Disposition kinetics of ropivacaine in humans. Anesth Analg 69:736–738

    Article  PubMed  CAS  Google Scholar 

  360. Kopacz DJ, Emanuelsson BM, Thomson GE, Carpenter RL, Stephenson CA (1994) Pharmacokinetics of ropivacaine and bupivacaine in healthy male volunteers. Anesthesiology 81:1139–1148

    Article  PubMed  CAS  Google Scholar 

  361. Katz JA, Bridenbough PO, Knarr DC, Helton SH, Denson DD (1990) Pharmacodynamics and pharmacokinetics of epidural ropivacaine in humans. Anesth Analg 70:16–21

    Article  PubMed  CAS  Google Scholar 

  362. Morrison LMM, Emanuelsson BM, McClure JH, Pollok AJ, McKeown DW, Brockway M, Jozwiak H, Wildsmith JA (1994) Efficacy and kinetics of extradural ropivacaine: comparison with bupivacaine. Br J Anaesth 72:164–169

    Article  PubMed  CAS  Google Scholar 

  363. Brockway MS, Bannister J, McClure JH, McKeown D, Wildsmith JA (1991) Comparison of extradural ropivacaine and bupivacaine. Br J Anesth 66:31–37

    Article  CAS  Google Scholar 

  364. Oda Y, Furuichi K, Tanaka K, Hiroi T, Imaoka S, Asada A, Fujimori M, Funae Y (1995) Metabolism of a new local anaesthetic, ropivacaine, by human hepatic cytochrome p450. Anesteshiology 82:214–220

    Article  CAS  Google Scholar 

  365. deJong RH (1995) Gaston labat lecture. Ropivacaine. White knight or dark horse? Reg Anesth 20:474–481

    CAS  Google Scholar 

  366. Hickey R, Hoffman J, Ramamurthy S (1991) A comparison of ropivacaine 0,5 % and bupivacaine 0,5 % for brachial plexus block. Anesthesiology 74:639–642

    Article  PubMed  CAS  Google Scholar 

  367. van Kleef JW, Veering BT, Burm AGL (1994) Spinal anesthesia with ropivacaine: a double-blind study on the efficacy and safety of 0,5 % and 0,75 % solutions in patients undergoing minor lower limb surgery. Anesth Analg 78:1125–1130

    PubMed  Google Scholar 

  368. Badner NH, Reid D, Sullivan P, Ganapathy S, Crosby ET, McKenna J, Lui A (1996) Continuous epidural infusion of ropivacaine for the prevention of postoperative pain after major orthopaedic surgery: a dose-finding study. Can J Anesth 43:17–22

    Article  PubMed  CAS  Google Scholar 

  369. Stienstra R, Jonker TA, Bourdrez P, Kuijpers JC, van Kleef JW, Lundberg U (1995) Ropivacaine 0,25 % versus bupivacaine 0,25 % for continuous epidural analgesia in labor: a double-blind comparison. Anesth Analg 80:285–289

    PubMed  CAS  Google Scholar 

  370. Kerkamp HEM, Gielen MJM (1991) Cardiovascular effects of local anaesthetics. Anaesthesia 46:361–365

    Article  Google Scholar 

  371. Wolff AP, Hasselstroem L, Kerkkamp HE, Gielen MJ (1990) Extradural ropivacaine and bupivacaine in hip surgery. Br J Anesthesia 64:67–71 1. Drug Fut (1995) 20(1):19-23

    Article  Google Scholar 

  372. Abramsky O, Lehmann D, Karassis D (1996) Immunomodulation with linomide: possible novel therapy for multiple sclerosis. Mult Scler 2:206–210

    PubMed  CAS  Google Scholar 

  373. Anderson O, Lycke J, Tollesson PO et al. (1996) Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurol 47:895–900

    Article  Google Scholar 

  374. Borgstrom P, Torres Filho IP, Vajkoczy P et al. (1994) The quinoline-3-carboxamide linomide inhibits angiogenesis in vivo. Cancer Chemother Pharmacol 34:280–286

    Article  PubMed  CAS  Google Scholar 

  375. Diab A, Michael L, Wahren B et al. (1998) Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines. J Neuroimmunol 85:146–154

    Article  PubMed  CAS  Google Scholar 

  376. Ekstrom PA, Hedlund G, Karlsson J et al. (1998) The immune modulator linomide prevents neuronal death in injured peripheral nerves of the mouse. Neuroreport 9:1337–1341

    Article  PubMed  CAS  Google Scholar 

  377. Eralinna JP, Roytta M, Hukkanen V et al. (1998) Selective downregulation of Th1 response by linomide reduces autoimmunity but increases susceptibility to viral infection in BALB/c and SJL mice. J Neuroimmunol 88:165–176

    Article  PubMed  CAS  Google Scholar 

  378. Gonzalo JA, Gonzalez-Garcia A, Kalland T et al. (1993) Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur J Immunol 23:2372–2374

    Article  PubMed  CAS  Google Scholar 

  379. Gonzalo JA, Gonzalez-Garcia A, Kalland T et al. (1994) Linomide inhibits programmed cell death of peripheral T cells in vivo. Eur J Immunol 24:48–52

    Article  PubMed  CAS  Google Scholar 

  380. Gross DJ, Weiss L, Reibstein I et al. (1998) Amelioration of diabetes in nonobese diabetic mice with advanced disease by linomide-induced immunoregulation combined with Reg protein treatment. Endocrinol 139:2369–2374

    Article  CAS  Google Scholar 

  381. Joseph IB, Isaacs JT (1996) The antiangiogenic agent linomide inhibits tumor necrosis factor-alpha secretion via inhibition of its synthesis. Prostate 29:183–190

    Article  PubMed  CAS  Google Scholar 

  382. Karussis DM, Meiner Z, Lehmann D et al. (1996) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resoncance imaging evaluation. Neurol 47:341–346

    Article  CAS  Google Scholar 

  383. Lehmann D, Karassis D, Mizrachi-Koll R et al. (1997) Inhibition of the progression of multiple sclerosis by linomide is associated with upregulation of CD4+/CD45RO+ cells. Clin Immunol Immunopath 85:202–209

    Article  CAS  Google Scholar 

  384. Lepisto J, Laato M, Niinikoski J et al. (1994) Stimulation of wound healing by the immunomodulator LS-2616 (linomide) World J Surg 18:818–820 (Diskuss.)

    PubMed  CAS  Google Scholar 

  385. Rosenfeld CS, Zeigler ZR, Shadduck RK et al. (1997) Phase II study of roquinimex in myelodysplastic syndrome. Am J Clin Oncol 20:189–192

    Article  PubMed  CAS  Google Scholar 

  386. Shoenfeld Y (1994) Immunosupppression of experimental systemic lupus erythematosus and antiphospholipid syndrome. Transpl Proc 26:3211–3213

    CAS  Google Scholar 

  387. Slavin S, Gross D, Weiss (1995) Prevention and treatment of type I diabetes in NOD mice by linomide. Transpl Proc 27:3240

    CAS  Google Scholar 

  388. Tian WZ, Navikas V, Matusevicius D et al. (1998) Linomide (roquinimex) affects the balance between pro-and anti-inflammatory cytokines in vitro in multiple slcerosis. Acta Neurol Scand 98:94–101

    Article  PubMed  CAS  Google Scholar 

  389. Wanders A, Larsson E, Gergin B et al. (1989) Abolition of the effect of cyclosporine on rat cardiac allograft rejection by the new immunomodulator LS-2616 (linomide). Transpl 47:216–217

    Article  CAS  Google Scholar 

  390. Xiao BG, Bail XF, Zhang GX et al. (1998) Linomide-mediated protection of oligodendrocytes is associated with inhibition of nitric oxide production and IL-1beta expression in Lewis rat glial cells. Neurosci Lett 249:17–20

    Article  PubMed  CAS  Google Scholar 

  391. Zandman-Goddard G, George J, Levy Y et al. (1996) Modulation of experimental systemic lupus erythematosus with linomide. Lupus 5:328–333

    Article  PubMed  CAS  Google Scholar 

  392. Zhang GX, Yu LY, Shi FD et al. (1998) Cytokine profiles of experimental autoimmune myasthenia gravis after treatment by the synthetic immunomodulator linomide. Ann N Y Acad Sci 841:580–583

    Article  PubMed  CAS  Google Scholar 

  393. Ziche M, Donnini S, Morbidelli L et al. (1998) Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants. Brit J Cancer 77:1123–1129

    Article  PubMed  CAS  Google Scholar 

  394. Hausberg HH, Koppe V, Poetsch E, Saiko O, Seyfried C (Merck Patent GmbH) EP 007399, zit. nach Lit. 2

    Google Scholar 

  395. Robinson C, Castañer J (1995) Drugs Fut 20:1228–1232

    Google Scholar 

  396. Hausberg HH, Böttcher H, Seyfried C, Bergmann R (Merck Patent GmbH) EP 166183, JP 85258117, US 4711893, DE 3419935, zit. nach Lit. 2

    Google Scholar 

  397. Böttcher H, Barnickel G, Hausberg HH, Haase AF, Seyfried CA, Eiermann V (1992) J Med Chem 35:4020–4026

    Article  PubMed  Google Scholar 

  398. Robinson C (1995) Drugs Fut 20:148–152

    Google Scholar 

  399. Barone AD, Ghrayeb J, Hammerling U, Zucker MB, Thorbecke GJ (1988) J Biol Chem 263:8710–8715

    PubMed  CAS  Google Scholar 

  400. Hermodson M, Schmer G, Kurachi K (1977) J Biol Chem 252:6276–6279

    PubMed  CAS  Google Scholar 

  401. Maione TE, Gray GS, Petra J, Hunt AJ et al. (1990) Science 247:77–79

    Article  PubMed  CAS  Google Scholar 

  402. Zhang X, Chen L, Bancroft DP (1994) Biochem 33:8361–8366

    Article  CAS  Google Scholar 

  403. Cecchetti V, Fravolini A, Friguelli R, Mascellani G, Pagella P, Palmioli M, Segre G, Terni P (1987) J Med Chem 30:465–473

    Article  PubMed  CAS  Google Scholar 

  404. Carlucci G, Mazzeo P, Fanini D, Palumbo D (1991) Ther Drug Monit 13:448

    Article  PubMed  CAS  Google Scholar 

  405. Vree TB, Vandenbiggelaarmartea M, Peeters A, Imbimbo BP (1992) J Chromatogr Biomed Appl 573:168

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

von Bruchhausen, F. et al. (1999). R. In: von Bruchhausen, F., et al. Hagers Handbuch der Pharmazeutischen Praxis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-58388-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-58388-9_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63569-4

  • Online ISBN: 978-3-642-58388-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics